Supplementary Data

Potential Utility of Soluble p3-Alcadeinα Plasma Levels as a Biomarker for Sporadic Alzheimer’s Disease

Kenji Kamogawa, Katsuhiko Kohara, Yasuharu Tabara, Rie Takita, Tetsuro Maki, Tomoko Kommo, Saori Hata and Toshiharu Suzuki

Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan
Department of Basic Medical Research and Education, Ehime University Graduate School of Medicine, Ehime, Japan
Proteo-Medicine Research Center, Ehime University Graduate School of Medicine, Ehime, Japan
Department of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Hokkaido, Japan

Accepted 13 April 2012
Supplementary Figure 1. Schematic diagram of amyloid-β precursor protein (AβPP) and Alcadein (Alc) metabolisms. Alc is cleaved successively by α-secretase followed by γ-secretase, resulting in the release of p3-Alc. Since p3-Alc is not aggregated like amyloid-β (Aβ), p3-Alc is detectable in human cerebrospinal fluid (CSF) and blood [1, 2].

Supplementary Figure 2. Schematic diagram of p3-Alcadein fragments following γ-secretase cleavage. p3-Alcadein35 (p3-Alc35), a peptide that includes the sequence from Ala817 to Thr852 of Alcadein1, is a major molecule of p3-Alc γ-secretase cleavage. Functional alteration of the enzyme can increase minor molecules [1, 3].
REFERENCES

